

****New release July 2010****

MarketVIEW: Yellow Fever vaccines (CAT: VAMV019)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	MarketVIEW: Yellow Fever vaccines – Global market forecast
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	<i>Novel/travel vaccines</i>
Product (if applicable)	:	CAT No: VAMV019, published July 2010

Background

Yellow Fever (YF) is a mosquito-borne disease caused by the *Amaril* virus which has symptoms that range from mild to severe illness and even death (est 30,000/yr). The disease, which exists in various forms, is mainly endemic to parts of Africa and Latin America (LATAM) where 610 million are estimated to be at risk of which 219 million are living in urban settings.

Yellow fever vaccination, using a one shot live-attenuated vaccine based on 17-D is the most important measure to control YF and has been available for decades. It is currently used in routine childhood immunization (6-9 mos) and as part of donor funded mass vaccination campaigns operated by the YF initiative (WHO/UNICEF). YF vaccine is also used by Western travelers (YF-VAX, Stamaril, Sanofi Pasteur) to endemic regions where certification is required for entry. Various militaries also use YF vaccine for troops stationed in certain areas.

This **MarketVIEW** product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Yellow Fever vaccination across endemic, travelers and military markets to 2030. The model contains value (\$ m) and volume (mio doses) predictions/with supplier volume analysis. **LO/BASE/HI** forecast scenarios are included based upon expected demand from further YF initiative activities (planned and unplanned). Safety considerations of current vaccines are discussed along with new inactivated vaccines e.g. Xcellerex Inc are discussed along with other live-attenuated approaches e.g. Crucell's Flavimun.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Yellow Fever epidemiology/vaccines and. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of travel and endemic vaccines has also been utilised.

PRODUCT CONTENTS:

Published July 2010 (CAT No: VAMV019)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Author's note

Executive Summary

Commercial model – key outputs

Yellow Fever vaccine – total predicted volume (\$ 000s): all scenarios

Yellow Fever vaccine – total predicted market (\$ 000s): all scenarios

Yellow Fever vaccine – supplier volume analysis to 2020

Yellow Fever vaccine: segment value analysis (\$ 000s)

Yellow Fever Map – countries or areas at risk of transmission, 2007

Yellow Fever – countries where disease is present

Yellow Fever vaccines: YF-17D

Yellow Fever vaccines: Arilvax

Yellow Fever vaccines: WHO prequalified suppliers

Yellow Fever vaccines: adverse events

Yellow Fever vaccines: adverse events (US VAERS)

Yellow Fever vaccines: other contraindications/precautions

Yellow Fever vaccine opportunity: target product profile

Yellow Fever vaccine: population segments included in model (scenario definition)

Broad market classifications for a Yellow Fever vaccine

The Yellow Fever Initiative (YFI)

YF vaccine: countries with routine childhood immunization

YFI: Progress of mass preventative campaigns

Commercial model assumptions: routine childhood (<1 yrs)

Commercial model assumptions: additional mass campaigns

Quantification: additional mass campaigns

Western travelers: major commercial model assumptions

Backup material

R&D YF vaccines: Flavimun

R&D YF vaccines: Xcellerex Inc

YF vaccines: key potential market upsides

Sanofi Pasteur: travel vaccine portfolio 2003 – 2009

Bibliography

About VacZine Analytics

Disclaimer

PAGES: 40 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title sheet
Scenario definitions
Scenario value/volume charts
Supplier volume analysis
Travel Mil vol val summary
< 1yrs value summary
< 1yrs volume summary
Routine Child YF initiative =>
<1 yrs Benin
<1 yrs Burkina Faso
<1 yrs Cameroon
<1 yrs Central African Republic
<1 yrs Cote D'Ivoire
<1 yrs Cameroon
<1 yrs Central African Republic
<1 yrs Ghana
<1 yrs Guinea
<1 yrs Liberia
<1 yrs Mali
<1 yrs Nigeria
<1 yrs Senegal
<1 yrs Sierra Leone
<1 yrs Togo
<1 yrs other Africa (routine)
<1 yrs other Africa (non-routine)
Routine child (LATAM)
< 1 yrs Brazil (public)
< 1 yrs other LATAM (public)
Western Travelers
US
EU
Japan
Source material
YF endemic – Total pop > 2010
YF endemic – Birth cohort > 2010
YF vaccination coverage 05-09
YF campaigns Africa + LATAM
Traveler databases
Back-page

WORKSHEETS: ~65

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o USD \$7995.00/ GBP £5499.00 (Region license)*


*A region is North America, Europe or ROW

For orders in the UK, VAT at 17.5% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. Centers for Disease Control and Prevention. Yellow Fever Global Map. Available at: http://www.cdc.gov/ncidod/dvbid/yellowfever/YF_GlobalMap.html. Accessed June 2010
2. Yellow Fever. Recommendations of the Advisory Committee on Immunization Practices (ACIP). Available at: <http://www.cdc.gov/mmwr/PDF/rr/rr5117.pdf>. Accessed June 2010
3. Sanofi Pasteur MSD. Available at: <http://www.spmsd.co.uk/productPage.asp?catid=96>. Accessed June 2010
4. Belmusto-Worn VE., Randomized, double-blind Phase III, pivotal field trial of the comparative immunogenicity, safety and tolerability of two yellow fever 17D vaccines (Arixax[™] and YF-VAX) in healthy infants and children. 2005. Am J.Trop. Med. Hyg. 72(2) pp 189-187
5. The World Health Organisation. Yellow Fever Initiative. Providing an opportunity of a lifetime. Available at: <http://www.who.int/csr/disease/yellowfev/YFbrochure.pdf>. Accessed June 2010
6. Financial threat to global supply of vaccine puts 120 million at risk of yellow fever. UNICEF News Note. 16 June 2010. Available at: http://www.unicef.org/media/media_53980.html. Accessed June 2010
7. Sanofi Pasteur Press Kit. Available at: http://www.avpi.org/sanofi-pasteur2/ImageServlet?imageCode=27494&siteCode=SP_CORP. Accessed June 2010
8. US Centers For Disease Control and Prevention. Adverse events associated with 17-D-derived yellow fever vaccination: United States. 2001-2002. MMWR Morb Mortal Wkly Rep 2002; 51: 989-93
9. Khromava AY., et al. Yellow Fever vaccine: An updated assessment of advanced age as a risk factor for serious Events. Vaccine 23 (2005) 3256-3263
10. Khromava AY., et al. Yellow Fever vaccine: An updated assessment of advanced age as a risk factor for serious Events. Vaccine 23 (2005) 3256-3263
11. Nasidi A., et al Yellow fever vaccination and pregnancy: a four year prospective study. Trans R Soc Trop Med Hyg. 1993; 87: 337-9
12. Goujon C et al. Good Tolerance and efficacy of Yellow Fever vaccine among subject carriers of HIV virus [abstract 32]. Presented at the 4th International Conference on Travel Medicine. Acapulco, Mexico April 23-27, 1995
13. World Health Organisation. Immunization monitoring. Available at: http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm. Accessed June 2010
14. Data used is from World Tourism Organisation (2020 Vision)
15. Figures are taken from Market Assessment for Malaria Vaccines. The Boston Consulting Group. January 2005.
16. Khromava AY., et al. Yellow Fever vaccine: An updated assessment of advanced age as a risk factor for serious Events. Vaccine 23 (2005) 3256-3263
17. Merrill Lynch. Biotechnology. Global Vaccines – Plague, Pestilence and PE's. 7 January 2003
18. Belmusto-Worn VE., Randomized, double-blind Phase III, pivotal field trial of the comparative immunogenicity, safety and tolerability of two yellow fever 17D vaccines (Arixax[™] and YF-VAX) in healthy infants and children. 2005. Am J.Trop. Med. Hyg. 72(2) pp 189-187
19. Crucell Corporation Website. Available at: http://www.crucell.com/R_and_D-Clinical_Development-Yellow_Fever_Vaccine. Accessed June 2010
20. Xcellerex Initiates Phase I clinical trial of Novel Yellow Fever Vaccine. Available at: http://www.xcellerex.com/pdf/YF_Phase_I_initiation_final.pdf. Accessed June 2010

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and "the spiral logo" are UK Registered Trademarks, 2009